Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Autism Spectrum Disorder (ASD)

DMT for Autism Spectrum Disorder (ASD)

1 paper and 0 clinical trials exploring dmt as a treatment for autism spectrum disorder (asd).

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 1 in 160 children worldwide.

Autism Spectrum Disorder (ASD)

Research into the use of psychedelics for treating Autism Spectrum Disorder (ASD) is limited but gaining traction, with preliminary studies suggesting potential therapeutic benefits, particularly for associated social anxiety. Notable figures in this emerging field, such as Alicia Danforth and Charles Grob, are advocating for further exploration of psychedelics in ASD treatment.

Full Autism Spectrum Disorder (ASD) profile

Academic Research

1 paper
Open Accessmeta

Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder

This review evaluates evidence that serotonergic psychedelics (5‑HT2A agonists such as LSD, psilocybin and DMT) may ameliorate social deficits and co‑occurring anxiety and depression in autism spectrum disorder. It highlights neurobiological constraints (synaptic, serotonergic, prefrontal and thalamocortical dysfunction), mixed and sometimes adverse outcomes in historical paediatric trials, and concludes that rigorous contemporary studies are needed to determine whether benefits outweigh risks and whether 5‑HT2A is a viable therapeutic target.

Published
January 27, 2022
Journal
Frontiers in Pharmacology
Authors
Markopoulos, A., Inserra, A., De Gregorio, D., Gobbi, G.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Autism Spectrum Disorder (ASD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Autism Spectrum Disorder (ASD) trials Full DMT profile Full Autism Spectrum Disorder (ASD) profile